Vaxfectin™-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge

Human Vaccines

Volumn 3, Issue 5, 2007, Pages 157-164

  Jimenez, Gretchen S ^a   Planchon, Rodrick ^a   Wei, Qun ^a   Rusalov, Denis ^a   Geall, Andrew ^a   Enas, Joel ^a   Lalor, Peggy ^a   Leamy, Vicky ^a   Vahle, Ruth ^a   Luke, Catherine J ^b   Rolland, Alain ^a   Kaslow, David C ^a,c   Smith, Larry R ^a  

^a VICAL INC   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

DNA vaccine; Influenza virus; Vaxfectin

Indexed keywords

DNA VACCINE; INFLUENZA VACCINE; PLASMID DNA; POLOXAMER; PROTEIN M2; PROTEIN NP; UNCLASSIFIED DRUG; VAXFECTIN; VIRUS PROTEIN; CORE PROTEIN; IMMUNOLOGICAL ADJUVANT; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; NP PROTEIN, INFLUENZA A VIRUS; NUCLEOPROTEIN; PHOSPHATIDYLETHANOLAMINE; RNA BINDING PROTEIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG FORMULATION; IMMUNOGENICITY; INFECTION PREVENTION; INFLUENZA; LOW DRUG DOSE; MOUSE; NONHUMAN; PROVOCATION TEST; ANIMAL; BAGG ALBINO MOUSE; BLOOD; GENETICS; IMMUNOLOGY; ORTHOMYXOVIRUS INFECTION; SURVIVAL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NUCLEOPROTEINS; ORTHOMYXOVIRIDAE INFECTIONS; PHOSPHATIDYLETHANOLAMINES; RNA-BINDING PROTEINS; SURVIVAL ANALYSIS; VACCINATION; VACCINES, DNA; VIRAL CORE PROTEINS; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 35348960407     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.3.5.4175     Document Type: Article

References (30)

1. Gerdil C. The annual production cycle for influenza vaccine. Vaccine 2003; 21:1776-9.
2. Potter CW. A history of influenza. J Appl Microbiol 2001; 91:572-9.
3. Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv Genet 2005; 55:25-40.
4. Manthorpe M, Hobart P, Hermanson G, Ferrari M, Geall A, Goff B, Rolland A. Plasmid vaccines and therapeutics: From design to applications. Adv Biochem Eng Biotechnol 2005; 99:41-92.
5. Hartikka J, Bozoukova V, Ferrari M, Sukhu L, Enas J, Sawdey M, Wloch MK, Tonsky K, Norman J, Manthorpe M, Wheeler CJ. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 2001; 19:1911-23.
6. Reyes L, Harrikka J, Bozoukova V, Sukhu L, Nishioka W, Singh G, Ferrari M, Enas J, Wheeler CJ, Manthorpe M, Wloch MK. Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine 2001; 19:3778-86.
7. D'Souza S, Rosseels V, Denis O, Tanghe A, De Smet N, Jurion F, Paifliet K, Castiglioni N, Vanonckelen A, Wheeler C, Huygen K. Improved tuberculosis DNA vaccines by formulation in cationic lipids. Infect Immun 2002; 70:3681-8.
8. Sedegah M, Rogers WO, Belmonte A, Belmonte M, Banania G, Patterson N, Ferrari M, Kaslow DC, Carucci DJ, Richie TL, Doolan DL. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine 2006; 24:1921-7.
9. Hermanson G, Whidow V, Parker S, Tonsky K, Rusalov D, Ferrari M, Lalor P, Komai M, Mere R, Bell M, Brenneman K, Mateczun A, Evans T, Kaslow D, Galloway D, Hobart P. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA 2004; 101:13601-6.
10. Margalith M, Vilalta A. Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine. Genet Vaccines Ther 2006; 4:2.
11. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259:1745-9.
12. Robinson HL, Boyle CA, Feltquate DM, Morin MJ, Santoro JC, Webster RG. DNA immunization for influenza virus: Studies using hemagglutinin- and nucleoprotein-expressing DNAs. J Infect Dis 1997; 176:S50-5.
13. Chen Z, Yoshikawa T, Kadowaki S, Hagiwara Y, Matsuo K, Asanuma H, Aizawa C, Kurata T, Tamura S. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J Gen Virol 1999; 80(Pt 10):2559-64.
14. Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, Hamajima K, Yang J, Ishii N, Nakazawa M, Ohnari K, Nakajima K, Xin KQ. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine 2001; 19:3681-91.
15. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, Renshaw M, Sambhara S, Katz JM. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis 2002; 8:796-801.
16. Donnelly JJ, Friedman A, Ulmer JB, Liu MA. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine 1997; 15:865-8.
17. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: Weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004; 172:5598-605.
18. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999; 5:1157-63.
19. Fan J, Liang X, Horton MS, Perry HC, Cirron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chasrain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW. Preclinical srudy of influenza virus A M2 peptide conjugate vaccines in mice, ferrers, and rhesus monkeys. Vaccine 2004; 22:2993-3003.
20. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. Passively Transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 1990; 64:1375-7.
21. Selinsky C, Luke C, Wloch M, Geall A, Hermanson G, Kaslow D, Evans T. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Human Vaccines 2005; 1:16-23.
22. Macken C, Lu H, Goodman J, Boykin L. The value of a database in surveillance and vaccine selection. In: Osterhaus ADME, Cox N, Hampson AW, eds. Options for the control of influenza IV. Amsterdam: Elsevier Science, 2001:103-06.
23. Wheeler CJ, Sukhu L, Yang G, Tsai Y, Bustamente C, Felgner P, Norman J, Manthorpe M. Converting an alcohol to an amine in a cationic lipid dramatically alters the colipid requirement, cellular transfection activity and the ultrastructure of DNA-cytofectin complexes. Biochim Biophys Acta 1996; 1280:1-11.
24. Sasaki S, Amara RR, Yeow WS, Pitha PM, Robinson HL. Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. J Virol 2002; 76:6652-9.
25. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood JM, Ypma E, Zambon MC. Safety and antigenicity of nonadjuvanted and MF-59-adjuvanted influenza A/Duck/Singapore/97 (H5N3): A randomised trial of two potential vaccines against H5N1 influenza. The Lancet 2001; 357:1937-43.
26. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz JM. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19:1732-7.
27. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-51.
28. Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: A potential priming strategy. J Infect Dis 2005; 191:1210-5.
29. Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood JM, Hoschler K, Zambon MC. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase 1 randomised trial. The Lancet 2006; 367:1657-64.
30. Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, Weiner DB. Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 2007; 25:2984-9.